CFDA cuts domestic pharma manufacturing inspections by more than half - news

Location: Policy & Industy - policy

Policy & Industy

I have question

CFDA cuts domestic pharma manufacturing inspections by more than half

China's Food and Drug Administration (CFDA) was found to have inspected less than half of the number of domestic pharmaceutical manufacturing sites as compared with 2014 according to an annual report from CFDA's Center for Food and Drug Inspection, reports Regulatory Focus.

Despite the decline in site inspections, the percentage of sites experiencing rectification inspections and issuance of warning letters increased by 13%.

The report's findings follow recent decisions by the U.S. FDA to closely watch the Chinese drug market for noncompliant domestic pharmaceutical manufacturers.

SOURCE: BioPharma Dive

2003-2012©

China Medicinal Biotech Association

phome: +86 10 62115986,62126275,67044735,67044736

Fax: +86 10 62115976

E-mail:cmba@cmba.org.cn